Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 401–500 of 1,000
Poon, M., & Lee, A. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0096-y · Cited by 40
“The superiority of primary prophylaxis (for definition, see Table 1) compared to episodic treatment is no longer questioned based on pivotal randomized controlled studies [3, 4].”
BackgroundCurry, N. S., Albayrak, C., Escobar, M. A., Holme, P. A., Kearney, S. L., Klamroth, R., Misgav, M., Négrier, C., Wheeler, A. P., Santagostino, E., et al. (2019) · Haemophilia · doi:10.1111/hae.13712 · Cited by 37
Joint status of patients with nonsevere hemophilia A
Zwagemaker, A., Kloosterman, F. R., Hemke, R., Gouw, S. C., Coppens, M., Romano, L. G. R., Kruip, M. J. H. A., Cnossen, M. H., Leebeek, F. W. G., Hutten, B. A., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15676 · Cited by 37
“Synovial hypertrophy 0 (0) 0 (0) 0 (0) 0 (0) 3 (14) 0 (0) 3 (2)”
InfluentialThornburg, C. D., Carpenter, S. L., Zappa, S. C., Munn, J. E., & Leissinger, C. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02756.x · Cited by 37
Self-citationFischer, K., Valentino, L. A., Ljung, R. C. R., & Blanchette, V. S. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01736.x · Cited by 37
Self-citationvan Leeuwen, F. H. P., van Bergen, E. D. P., Timmer, M. A., van Vulpen, L. F. D., Schutgens, R. E. G., de Jong, P. A., Fischer, K., & Foppen, W. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.01.035 · Cited by 36
Gene therapy for hemophilia: past, present and future
George, L. A., & Fogarty, P. F. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.002 · Cited by 37
Shapiro, A. D. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.819339 · Cited by 37
“Prophylaxis in young children has been shown to prevent joint damage compared with episodic treatment [2,4,5].”
BackgroundSelf-citationPharmacokinetics and pharmacodynamics of turoctocog alfa and N8 ‐ GP in haemophilia A dogs
Agersø, H., Stennicke, H. R., Pelzer, H., Olsen, E. N., Merricks, E. P., DeFriess, N., Nichols, T. C., & Ezban, M. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02896.x · Cited by 36
Biological Rationale for New Drugs in the Bleeding Disorders Pipeline
Fogarty, P. F. (2011) · Hematology · doi:10.1182/asheducation-2011.1.397 · Cited by 38
Roca, C. A., Román, M. T. Á., Canaro, M., Mingot‐Castellano, M. E., Jiménez‐Yuste, V., Haro, A. R. C., Pérez‐Garrido, R., Balbas, C. S., & Fernández, M. F. L. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0568 · Cited by 36
“Introduction Patients with severe haemophilia A without inhibitors against factor VIII (FVIII) can benefit from prophylactic therapy with FVIII, an approach that has been shown to be effective in preventing joint bleeding and arthropathy in these patients (1, 2).”
BackgroundExtended half‐life factor VIII for immune tolerance induction in haemophilia
Malec, L. M., Journeycake, J. M., & Ragni, M. V. (2016) · Haemophilia · doi:10.1111/hae.13064 · Cited by 36
The impact of extended half-life versus conventional factor product on hemophilia caregiver burden
Schwartz, C. E., Powell, V. E., Su, J., Zhang, J., & Eldar‐Lissai, A. (2018) · Quality of Life Research · doi:10.1007/s11136-018-1792-9 · Cited by 36
“It is particularly recommended for patients with severe forms of hemophilia because it improved patient outcomes [19].”
BackgroundGao, K., Kumar, P., Cortez-Toledo, E., Hao, D., Reynaga, L., Rose, M. D., Wang, C., Farmer, D. L., Nolta, J. A., Zhou, J., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1138-8 · Cited by 40
“Currently, the standard of care for these patients is FVIII protein substitution therapy (PST) with repeated intravenous injection of the FVIII concentrates derived from human plasma or the FVIII protein generated through recombinant DNA technology [3, 4].”
BackgroundBone density and health-related quality of life in adult patients with severe haemophilia
KHAWAJI, M., Astermark, J., Mackensen, S. V., Åkesson, K., & Berntorp, E. E. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02423.x · Cited by 36
Nugent, D. J., Kalnins, W., Querol, F., Gregory, M., Pilgaard, T., Cooper, D. L., & Iorio, A. (2014) · Haemophilia · doi:10.1111/hae.12545 · Cited by 36
Self-citationPain therapy in haemophilia in Germany
Schelle, G., Jost, K. C., Jr., Eberl, W. R., Tiede, A., & Kalnins, W. (2014) · Hämostaseologie · doi:10.5482/hamo-14-03-0021 · Cited by 36
“Painful haemophilic arthropathy can be prevented in part by regular prophylaxis (20) and additional use of physiotherapy techniques including electrotherapy, joint care and exercise (21).”
BackgroundMøss, J., Rosholm, A., & Laurén, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04344.x · Cited by 35
Methods for individualising factor VIII dosing in prophylaxis
Ar, M. C., Vaide, I., Berntorp, E. E., & Björkman, S. E. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12370 · Cited by 35
Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs
Santagostino, E., Morfini, M., Auerswald, G., Benson, G. M., Šalek, S. Z., LAMBERT, T., Salaj, P., Jiménez‐Yuste, V., & Ljung, R. C. R. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.01999.x · Cited by 35
Early orthopaedic challenges in haemophilia patients and therapeutic approach
Seuser, A., Böhm, P., & Wermes, C. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2013.10.022 · Cited by 35
“Recent data show that even a small amount of blood in the joint can cause irreversible damage to the synovia and cartilage [2–4].”
BackgroundTiede, A., Oldenburg, J., Lissitchkov, T. J., Knaub, S., Bichler, J., & Manco‐Johnson, M. J. (2015) · Haemophilia · doi:10.1111/hae.12859 · Cited by 35
Self-citationPrimary prophylaxis in haemophilia care: Guideline update 2016
Fischer, K., & Ljung, R. C. R. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.02.004 · Cited by 35
RetractedAcharya, S. S., Rule, B., McMillan, O., & Humphries, T. J. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717690316 · Cited by 35
The art and science of choosing efficacy endpoints for rare disease clinical trials
Cox, G. F. (2018) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38629 · Cited by 35
“, 1992), bleeding episodes in severe hemophilia (Manco-Johnson et al., 2007), or bouts of herpes stromal keratitis (Herpetic EyeDisease Study Group, 2001).”
BackgroundTagliaferri, A., Franchini, M., Rivolta, G. F., Farace, S., Quintavalle, G., Coppola, A., & the ad hoc Study Group (2018) · Haemophilia · doi:10.1111/hae.13600 · Cited by 35
Kotani, N., Yoneyama, K., Kawakami, N., Shimuta, T., Fukase, H., & Kawanishi, T. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.617 · Cited by 37
Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine
Spadarella, G., Minno, A. D., Milan, G., Franco, N., Polimeno, M., Castaldo, F., & Minno, G. D. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100618 · Cited by 36
CRISPR technology for genome editing
Bhattacharjee, G., Mani, I., Gohil, N., Khambhati, K., Braddick, D., Panchasara, H., & Singh, V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00007-1 · Cited by 38
Schiavoni, M., Napolitano, M., Giuffrida, G., Coluccia, A., Siragusa, S. M., Calafiore, V., Lassandro, G., & Giordano, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00261 · Cited by 36
“For patients with severe HA, prophylaxis with FVIII concentrates is the main treatment regimen to reduce joint bleeding and other types of hemorrhage, thereby improving the health-related quality of life (HRQoL) of both patients and their caregivers (3, 4).”
BackgroundPharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice
Elm, T., Karpf, D. M., Øvlisen, K., Pelzer, H., Ezban, M., Kjalke, M., & Tranholm, M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02608.x · Cited by 35
Trakymienė, S. Š., Ingerslev, J., & Ragelienė, L. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02178.x · Cited by 35
Recombinant factor VIII in the management of hemophilia A: current use and future promise
Powell, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4412 · Cited by 35
Prophylaxis in von Willebrand disease
Berntorp, E. E. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01851.x · Cited by 34
van Meegeren, M. E., Roosendaal, G., Jansen, N. W. D., Lafeber, F. P. J. G., & Mastbergen, S. C. (2013) · Cartilage · doi:10.1177/1947603513497569 · Cited by 35
“It has been hypothesized that this is due to chronic micro-bleeds causing deterioration of the joints without a clinically apparent acute joint bleed.(3) Natural evacuation of blood from the joint cavity results in deposition of iron (hemosiderin) in the synovial tissue.”
BackgroundProgress in the contemporary management of hemophilia: The new issue of patient aging
Mannucci, P. M., & Iacobelli, M. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.05.012 · Cited by 34
Meeting the Needs of Culturally and Linguistically Different Students: A Handbook for Educators
Fradd, S. H., & Weismantel, M. J. (1989) · Cited by 35
Oldenburg, J., Goudemand, J., Valentino, L. A., Richards, M., LUU, H., Kriukov, A. Y., Gajek, H., Spotts, G. E., & Ewenstein, B. M. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02332.x · Cited by 34
Self-citationPowell, J. S., Shapiro, A. D., Ragni, M. V., Négrier, C., Windyga, J., Ozelo, M. C., Pasi, J., Baker, R. I., Potts, J., Li, S., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13109 · Cited by 34
Self-citationLamiani, G., Strada, I., Mancuso, M. E., Coppola, A., Vegni, E. A. M., Moja, E. A., & the Pro‐Adherence Study Group (2015) · Haemophilia · doi:10.1111/hae.12654 · Cited by 36
New developments in the management of moderate-to-severe hemophilia B
Sheehan, J. P., & Nazeef, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s81520 · Cited by 35
“7,8 In patients with severe hemophilia who are negative for HIV and inhibitors, prophylaxis also reduces the risk of central nervous system hemorrhage by about half.”
Low dose prophylaxis in Tunisian children with haemophilia
Gouider, E., Jouini, L., Achour, M., Elmahmoudi, H., Zahra, K., Saied, W., & Meddeb, B. (2016) · Haemophilia · doi:10.1111/hae.13048 · Cited by 34
Pasi, J., Fischer, K., Ragni, M. V., Nolan, B., Perry, D. J., Kulkarni, R., Ozelo, M. C., Mahlangu, J. N., Shapiro, A. D., Baker, R. I., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0398 · Cited by 34
Self-citationPredictors of quality of life among adolescents and young adults with a bleeding disorder
McLaughlin, J. M., Munn, J. E., Anderson, T. L., Lambing, A. Y., Tortella, B. J., & Witkop, M. (2017) · Health and Quality of Life Outcomes · doi:10.1186/s12955-017-0643-7 · Cited by 38
“However, differences in physical HRQoL (PCS) were not observed in our study, which is a surprising finding given that prophylaxis is associated with fewer joint bleeds and less pain [7], and a recent review found that joint status was associated with both social and emotional well-being [44].”
ResultPipe, S. W. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26865 · Cited by 37
“laxis, and (5) wider availability of replacement products for patients in developing countries.”
BackgroundChozie, N. A., Primacakti, F., Gatot, D., Setiabudy, R. D., Tulaar, A. B., & Prasetyo, M. (2019) · Haemophilia · doi:10.1111/hae.13770 · Cited by 34
“Total non‐joint bleeds 3 (2;8) 10 (8;17) <0.”
Furukawa, S., Nogami, K., Shimonishi, N., Nakajima, Y., Matsumoto, T., & Shima, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16574 · Cited by 34
“The development of regular prophylaxis with plasma-derived or recombinant FVIII products has dramatically improved the quality of lif in these patients (Manco-Johnson et al., 2007).”
BackgroundØvlisen, K., Kristensen, A. T., Valentino, L. A., HAKOBYAN, N., Ingerslev, J., & Tranholm, M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02954.x · Cited by 34
Self-citationHaemophilia care in children – benefits of early prophylaxis for inhibitor prevention
Mancuso, M. E., Graça, L., Auerswald, G., & Santagostino, E. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01947.x · Cited by 34
Fitness and quality of life in children with haemophilia
Broderick, C. R., Herbert, R., Latimer, J., & Curtin, J. A. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02096.x · Cited by 36
Shapiro, A. D., Gruppo, R. A., Pabinger, I., Collins, P. W., Hay, C. R. M., Schroth, P., Casey, K. B., Patrone, L., Ehrlich, H. J., & Ewenstein, B. M. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902729392 · Cited by 34
“Prophylaxis was pioneered in Sweden [3,4] , and is now documented to be superior to on-demand regimens in treating severe hemophilia A in clinical studies [5-12] , including a randomized study [13] .”
BackgroundResultSelf-citationLau, A. G., Sun, J., Hannah, W. B., Livingston, E. W., Heymann, D., Bateman, T. A., & Monahan, P. E. (2014) · Haemophilia · doi:10.1111/hae.12399 · Cited by 34
“In children, early institution of regular prophylactic clotting factor infusions to prevent hemarthrosis helps preserve joint function and is the standard of care in resource-rich countries [6].”
BackgroundA Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A
André, S., Meslier, Y., Dimitrov, J. D., Repessé, Y., Kaveri, S. V., Lacroix‐Desmazes, S., & Dasgupta, S. (2009) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8117-2 · Cited by 34
“activity of the synovial tissue as indicated by the development of arthropathy in patients with hemophilia A [38], leading to expansion and more permanent recruitment of inflammatory cells [39–41].”
BackgroundProcess of Normalization in Families With Children Affected by Hemophilia
Emiliani, F., Bertocchi, S., Potì, S., & Palareti, L. (2011) · Qualitative Health Research · doi:10.1177/1049732311417456 · Cited by 34
“Although the clinical benefits of prophylaxis are well established (Manco-Johnson et al., 2007), the present research has shown that prophylaxis requires intense cognitive, affective, and practical efforts to achieve family normality, which can be rediscovered by accepting the new condition and…”
BackgroundHenry, N., Jovanovic, J. V., Schlueter, M., Kritikou, P., Wilson, K., & Myrén, K.-J. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1405816 · Cited by 35
Spronck, E. A., Liu, Y. P., Lubelski, J., Ehlert, E., Gielen, S., Montenegro-Miranda, P. S., de Haan, M., Nijmeijer, B. A., Ferreira, V., Petry, H., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.005 · Cited by 34
“Importantly, factor replacement therapy does not always prevent spontaneous bleeds and may induce immune reactions to the replaced FIX(8,10,11) and does not completely prevent arthropathy, which may even occur in patients that have never reported a joint bleed.(12,13)”
BackgroundWhen should prophylaxis therapy in inhibitor patients be considered?
Young, G. A., Auerswald, G., Jiménez‐Yuste, V., Konkle, B. A., LAMBERT, T., Morfini, M., Santagostino, E., & Blanchette, V. S. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02494.x · Cited by 33
Rampersad, A. G., Shapiro, A. D., Rodriguez-Merchan, E. C., Maahs, J. A., Akins, S., & Jiménez‐Yuste, V. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3283602a28 · Cited by 33
Self-citationInnovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
“Currently, hemophilia A is treated with an intravenous infusion of plasma-derived or recombinant clotting FVIII concentrates, which can be on demand or prophylactic (8, 9).”
BackgroundHermans, C. R. J. R., Marino, R., Lambert, C., Mangles, S., Sommerer, P., Rives, V., Maro, G. S., & Malcangi, G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01300-6 · Cited by 33
Chowdary, P., Mullins, E. S., Konkle, B. A., McGuinn, C. E., Park, Y. S., Stasyshyn, O., Zülfikar, B., Engl, W., & Tangada, S. D. (2020) · Haemophilia · doi:10.1111/hae.14052 · Cited by 33
“Median (range) 4 (1-5) 7 (6-11) 14 (12-17) 32 (18-61) 20 (1-61)”
Song, X., Zhong, J., Xue, F., Chen, L., Li, H., Yuan, D., Xie, J., Shi, J., Zhang, L., Wu, E. Q., et al. (2020) · Haemophilia · doi:10.1111/hae.14217 · Cited by 39
Costs and utilization of hemophilia A and B patients with and without inhibitors
Armstrong, E. P., Malone, D. C., Krishnan, S., & Wessler, M. J. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.953679 · Cited by 33
“The ground-breaking clinical trial conducted by MancoJohnson et al.(9) found that use of Factor VIII prophylaxis in children reduced joint bleeding in boys.”
MethodHaemoassist™– a hand‐held electronic patient diary for haemophilia home care
Mondorf, W., Siegmund, B., MAHNEL, R., Richter, H., Westfeld, M., GALLER, A., & Pöllmann, H. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2008.01941.x · Cited by 37
A systematic review of MR imaging as a tool for evaluating haemophilic arthropathy in children
Chan, M. W., Leckie, A. E., Xavier, F., Uleryk, E. M., Tadros, S. S., Blanchette, V. S., & Doria, A. S. (2013) · Haemophilia · doi:10.1111/hae.12248 · Cited by 35
Cartilage damage in the haemophilic joints
Rodriguez-Merchan, E. C. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32835084dd · Cited by 33
Minno, G. D., Cerbone, A. M., Coppola, A., Cimino, E., Capua, M. D., Pamparana, F., Tufano, A., & Minno, M. N. D. D. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02155.x · Cited by 34
New approaches to gene and cell therapy for hemophilia
Ohmori, T., Mizukami, H., Ozawa, K., Sakata, Y., & Nishimura, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12926 · Cited by 30
The biological efficacy profile of BAX 855, a PEG ylated recombinant factor VIII molecule
Valentino, L. A., Cong, L., Enockson, C., Song, X., Scheiflinger, F., Muchitsch, E. M., Turecek, P. L., & HAKOBYAN, N. (2014) · Haemophilia · doi:10.1111/hae.12532 · Cited by 32
Self-citationHealthcare resource utilization among haemophilia A patients in the United States
Valentino, L. A., Pipe, S. W., Tarantino, M. D., Ye, X., XIONG, Y., & LUO, M. P. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02677.x · Cited by 32
Self-citationFischer, K., Carcao, M. D., Santagostino, E., Manco‐Johnson, M. J., Mathew, P., & Ljung, R. C. R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0664 · Cited by 32
Self-citationMåseide, R. J., Berntorp, E. E., Astermark, J., Olsson, A., Bruzelius, M., Frisk, T., Nummi, V., Lassila, R., Tjønnfjord, G. E., & Holme, P. A. (2020) · Haemophilia · doi:10.1111/hae.14114 · Cited by 32
“88 HJHS totald (0-120 points) 2 (0-10) 4 (1-9) .”
BackgroundSpinella, P. C., Kassar, N. E., Cap, A. P., Kindzelski, A., Almond, C. S. D., Barkun, A. N., Gernsheimer, T., Goldstein, J. N., Holcomb, J. B., Iorio, A., et al. (2021) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000003300 · Cited by 32
Königs, C., Ozelo, M. C., Dunn, A. L., Kulkarni, R., Nolan, B., Brown, S. A., Schiavulli, M., Gunawardena, S. W., Mukhopadhyay, S., Jayawardene, D. A., et al. (2022) · Blood · doi:10.1182/blood.2021013563 · Cited by 41
Skinner, M. W. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08765.x · Cited by 32
The hemophilias and their clinical management
Josephson, N. C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.261 · Cited by 33
Salvagno, G. L., Astermark, J., Lippi, G., Ekman, M., Franchini, M., Guidi, G. C., & Berntorp, E. E. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01877.x · Cited by 32
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Jackson, S. C., Yang, M., Minuk, L. A., Sholzberg, M., St-Louis, J., Iorio, A., Card, R., & Poon, M. (2015) · BMC Hematology · doi:10.1186/s12878-015-0022-8 · Cited by 31
“[3,4].”
Torres‐Ortuño, A., Cuesta‐Barriuso, R., & Nieto‐Munuera, J. (2014) · Haemophilia · doi:10.1111/hae.12471 · Cited by 31
Value of prophylaxis vs on‐demand treatment: Application of a value framework in hemophilia
Nugent, D. J., O’Mahony, B., & Dolan, G. (2018) · Haemophilia · doi:10.1111/hae.13589 · Cited by 31
“Six- country survey of 18- 35Y- old men with severe hemophilia4 Survey on longterm effects of prophylaxis vs on- demand treatment N = 124 Men with severe hemophilia A or B (FVIII/IX <1 IU/dL) Ages 18- 35 y Canada, France, Ireland, Netherlands, Poland, UK Respondent Groups:b (1) Always on- demand (2) <50% life on proph…”
BackgroundSelf-citationRadiosynovectomy in haemophilia
Rodriguez-Merchan, E. C. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.01.002 · Cited by 31
Hemophilia in a Changing Treatment Landscape
Pelland‐Marcotte, M., & Carcao, M. D. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.007 · Cited by 35
“Several clinical trials have shown clear superiority of prophylactic treatment with FVIII or FXI for severe hemophilia, compared with on-demand replacement.(2,3) Clearly the lives of persons with hemophilia were steadily improving throughout the 1970s.”
BackgroundAbrantes, J. A., Solms, A., Garmann, D., Nielsen, E. I., Jönsson, S., & Karlsson, M. O. (2019) · Haematologica · doi:10.3324/haematol.2019.217133 · Cited by 31
“Median [range] 1 [1-4] 2 [1-5] 1 [1-2] 1 [1-5]”
Malec, L. M., Cheng, D., Witmer, C. M., Jaffray, J., Kouides, P. A., Haley, K. M., Sidonio, R. F., Johnson, K. M., Recht, M., White, G., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25844 · Cited by 31
Self-citationProphylaxis for hemophilia A without inhibitors: treatment options and considerations
Valentino, L. A., & Khair, K. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1775576 · Cited by 33
“6, respectively, in the enhanced on-demand therapy group (N = 33) [28].”
BackgroundInfluentialSelf-citationO’Hara, S., Castro, F. A., Black, J. M., Chaplin, S., Ruiz, L., Hampton, R., Sima, C. S., & O’Hara, J. (2020) · Haemophilia · doi:10.1111/hae.14171 · Cited by 32
Oldenburg, J., Tran, H. A., Peyvandi, F., Núñez, R., Trask, P. C., Chebon, S., Mahlangu, J. N., Lehle, M., Jiménez‐Yuste, V., & Mackensen, S. V. (2021) · Haemophilia · doi:10.1111/hae.14270 · Cited by 32
Wilkins, R. A., Stephensen, D., Siddle, H. J., Scott, M. J., Xiang, H., Horn, E., Palmer, B., Chapman, G. J., Richards, M., Walwyn, R. E. A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-052358 · Cited by 31
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward
Lewandowska, M., Nasr, S., & Shapiro, A. D. (2022) · Haemophilia · doi:10.1111/hae.14531 · Cited by 32
Self-citationLow mortality from intracranial haemorrhage in paediatric patients with haemophilia
Witmer, C. M. (2015) · Haemophilia · doi:10.1111/hae.12716 · Cited by 31
Odds ratio vs risk ratio in randomized controlled trials
Balasubramanian, H., Ananthan, A., Rao, S. C., & Patole, S. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1022494 · Cited by 34
“4 [51] 28 Myburgh 2007 71 214 42 206 1.”
Challenges and controversies in haemophilia care in adulthood
Dolan, G., Hermans, C. R. J. R., Klamroth, R., Madhok, R., Schutgens, R. E. G., & Spengler, U. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01949.x · Cited by 31
The role of synovectomy in the management of a target joint
Llinás, A. M. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01763.x · Cited by 31
Jiménez‐Yuste, V., Rodriguez-Merchan, E. C., Alvarez, M. T., Quintana, M., Bello, I. F., & Hernandez-Navarro, F. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.03.009 · Cited by 31
Iorio, A., Krishnan, S., Myrén, K.-J., Lethagen, S., McCormick, N., Yermakov, S., & Karner, P. (2017) · Haemophilia · doi:10.1111/hae.13160 · Cited by 31
Assessments of outcome in haemophilia – what is the added value of QoL tools?
van den Berg, H. M., Feldman, B. M., Fischer, K., Blanchette, V. S., Poonnoose, P. M., & Srivastava, A. (2015) · Haemophilia · doi:10.1111/hae.12731 · Cited by 30
Giordano, P., Lassandro, G., Valente, M., Molinari, A. C., Ieranò, P., & Coppola, A. (2014) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2014.930768 · Cited by 34
“[20] and 25 IU/kg three times a week [12], respectively.”
BackgroundMethodResultInfluentialNijdam, A., Kurnik, K., Liesner, R. J., Ljung, R. C. R., Nolan, B., Petrini, P., Fischer, K., & the PedNet study group (2015) · Haemophilia · doi:10.1111/hae.12613 · Cited by 32
Understanding patient preferences and willingness to pay for hemophilia therapies
Chaugule, S., Hay, J. W., & Young, G. A. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s92985 · Cited by 30
“This is not surprising since prophylactic therapy is associated with better clinical outcomes.(4) In monetary terms, this preference corresponded to a mean WTP of $410 more out of pocket per month for the patients (Figure 2).”
BackgroundSung, J. J., Park, C., Leem, J. W., Cho, M. S., & Kim, D. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0243-1 · Cited by 31
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.